News and Analysis

Sparrow Pharmaceuticals rings in $50m Series A

Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company, has raised $50 million in Series A financing.

-

Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company, has raised $50 million in Series A financing. OrbiMed led the round with participation from RiverVest Venture Partners and U.S. Venture Partners.

Source: Press Release